For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Helixmith Co., Ltd

USPTO Granted Patents = 13

EPO Patents = 4

Trademarks = 2

Forward Citations = 1

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Jae-Gyun Jeong (4 out of 4 patents)

Seung Shin Yu (3 out of 6 patents)

Jae Gyun Jeong (3 out of 4 patents)

4. Doo Suk Lee (3 out of 4 patents)

5. Nayeon Lee (2 out of 2 patents)

6. Mi Won Son (2 out of 6 patents)

7. JungHun Lee (2 out of 20 patents)

8. Min Jung Bae (2 out of 2 patents)

9. Won Woo Lee (2 out of 4 patents)

10. Jung Hun Lee (2 out of 93 patents)

11. Kevin Friedman (1 out of 19 patents)

12. Jin-A Chae (1 out of 2 patents)

13. Dongsik Kim (1 out of 1 patent)

14. Juwon Shim (1 out of 1 patent)

15. Byeong Seon Chang (1 out of 15 patents)

13 patents: Sort by Forward Citations

1. 12180287 - Anti-c-Met antibody showing enhanced stability or antigen-binding fragments thereof (2024-12-31),

2. 11975039 - Herbal composition for treatment of attention deficit hyperactivity disorder (2024-05-07),

3. 11634728 - Adeno-associated virus (AAV) vector having hybrid HGF gene introduced thereto (2023-04-25),

4. 11559555 - Crude drug composition for preventing or treating respiratory diseases (2023-01-24),

5. 11554179 - Lyophilized pharmaceutical compositions for naked DNA gene therapy (2023-01-17),

6. 11541097 - Crude drug composition for preventing or treating respiratory diseases (2023-01-03),

7. 11510999 - Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms (2022-11-29),

8. 11279769 - Anti-Sialyl Tn chimeric antigen receptors (2022-03-22),

9. 11219667 - Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A (2022-01-11),

10. 10927177 - Methods of treatment using anti-c-met antibodies (2021-02-23),

11. RE48404 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2021-01-25),

12. 10759841 - Gene therapy for diabetic neuropathy using an HGF isoform (2020-09-01),

13. 10639351 - Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor (2020-05-05),

Helixmith Co., Ltd is a biopharmaceutical company that specializes in developing gene and cell therapies. With a focus on advanced regenerative medicine, the company aims to provide innovative solutions for various diseases, including genetic disorders, cancer, and rare diseases. Helixmith Co., Ltd strives to enhance patients' quality of life by delivering safe and effective therapies through cutting-edge research, advanced technology, and stringent quality control.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

13 Patents

#269 in Seoul

#834 in South Korea

#43,689 in the World

Seoul, South Korea

Helixmith Co., Ltd

Forward Citations = 1

26 inventors:

Jae-Gyun Jeong (4 out of 4 patents)

Seung Shin Yu (3 out of 6 patents)

Jae Gyun Jeong (3 out of 4 patents)

4. Doo Suk Lee (3 out of 4 patents)

5. Nayeon Lee (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…